Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 31, 2016 14:47:17 GMT -5
Iam, Yes indeed!! For whatever it is worth out here in the Jayhawk State in the Flint Hills. Just yesterday I mailed information from Kansas to California to a relative. I enclosed an inhaler, a couple cartridges and the enclosed instructions from a new box. I tell everyone that I know that is in need. The huge thing I think is that they don't believe that a billion dollar drug had not presence on TV or elsewhere. Somebody let Mannkind know that mass advertising creates demand that create mass sales. Can anyone recall a $2 billion drug that did not put $30 to $50 million into a mass adv. campaign? I cannot. On the advertising front they don't have the $&$ and didn't have the foresight to raise cash on FDA approval and several other occasion Its crazy how different things would be if they did the past two offerings 18 months ago. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 31, 2016 14:48:10 GMT -5
On the advertising front they don't have the $&$ and didn't have the foresight to raise cash on FDA approval and several other occasion Its crazy how different things would be if they did the past two offerings 18 months ago. its even crazier that the same CFO is now CEO |
|
|
|
Post by anthony7 on Oct 31, 2016 14:58:58 GMT -5
No
|
|
|
|
Post by mockingjay on Oct 31, 2016 15:20:12 GMT -5
Iam, Yes indeed!! For whatever it is worth out here in the Jayhawk State in the Flint Hills. Just yesterday I mailed information from Kansas to California to a relative. I enclosed an inhaler, a couple cartridges and the enclosed instructions from a new box. I tell everyone that I know that is in need. The huge thing I think is that they don't believe that a billion dollar drug had not presence on TV or elsewhere. Somebody let Mannkind know that mass advertising creates demand that create mass sales. Can anyone recall a $2 billion drug that did not put $30 to $50 million into a mass adv. campaign? I cannot. no, Sanofi did put 200Millions on afrezza |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 31, 2016 15:28:45 GMT -5
If the relative is not a pwd was he making sure it's real so he can invest? Lol |
|
|
|
Post by buyitonsale on Oct 31, 2016 15:37:19 GMT -5
Speaking of user experience... The scariest thing for me is that after thousands of new scripts, there are only about 600 patients (based on monthly refills numbers). You're wrongly assuming that all patients refill prescriptions every month when the truth is that many, if not most, refill every three months. For example, it's cheaper for me to refill my prescriptions every three months through my Caremark mail order plan than it would be to refill them every month at my local pharmacy. Check refills for the last 12 months and tell me how many patients are currently on Affrezza. Compare that number with NRx total. Whether refills are every 1 months or 3 months, still makes no sense. Refills also have not moved since July (which was 4 months ago). If in 3 months from now there are still 600 refills a month, what should we assume then? |
|
|
|
Post by gtay87 on Oct 31, 2016 15:44:50 GMT -5
Today's last couple of hours of trading were pretty frightening.
|
|
|
|
Post by silentknight on Oct 31, 2016 16:05:34 GMT -5
Today's last couple of hours of trading were pretty frightening. Days like this are the norm and will continue until MNKD does something to put a floor under their stock. The stock is manipulated by traders but is easy to drive down when the company can't point to many successes. The market cares about sales and profitability, either real or potential. So far, Afrezza hasn't demonstrated either. Patient testimonials are great but with no demand and insignificant sales, the market will punish any company in MNKDs position. We will be in the thirties by the time a CC is held most likely. Without a R/S, the stock will need a roughly 150% increase just to make Nasdaq compliance. Think about that. I'm still waiting for an announcement of a call, if there is one at all. |
|
|
|
Post by lakers on Oct 31, 2016 16:13:14 GMT -5
Today's last couple of hours of trading were pretty frightening. Days like this are the norm and will continue until MNKD does something to put a floor under their stock. The stock is manipulated by traders but is easy to drive down when the company can't point to many successes. The market cares about sales and profitability, either real or potential. So far, Afrezza hasn't demonstrated either. Patient testimonials are great but with no demand and insignificant sales, the market will punish any company in MNKDs position. We will be in the thirties by the time a CC is held most likely. Without a R/S, the stock will need a roughly 150% increase just to make Nasdaq compliance. Think about that. I'm still waiting for an announcement of a call, if there is one at all. 3Q16 ER will be on Mon 11/14/16. 10-Q needs to be filed within 45 days of qtr end. |
|
|
|
Post by anthony7 on Oct 31, 2016 17:20:02 GMT -5
No. She is 87 and a grand lady but not a computer person.
|
|
|
|
Post by kball on Oct 31, 2016 17:23:45 GMT -5
I dont see something scary as the silence is scary enough on another note joeypotsandpans did talk about invese H&S at one point of time. may be the technicians can chime in Didnt dude go into hibernation rip van winkle mode? Someone should wake him and let him know. That guy never worried. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 31, 2016 17:23:54 GMT -5
Days like this are the norm and will continue until MNKD does something to put a floor under their stock. The stock is manipulated by traders but is easy to drive down when the company can't point to many successes. The market cares about sales and profitability, either real or potential. So far, Afrezza hasn't demonstrated either. Patient testimonials are great but with no demand and insignificant sales, the market will punish any company in MNKDs position. We will be in the thirties by the time a CC is held most likely. Without a R/S, the stock will need a roughly 150% increase just to make Nasdaq compliance. Think about that. I'm still waiting for an announcement of a call, if there is one at all. 3Q16 ER will be on Mon 11/14/16. 10-Q needs to be filed within 45 days of qtr end. big multi national companies with complex financial structures file well before the deadlines. There is resource shortage at MNKD , but for such a simple report, this is beyond ridiculous. |
|
|
|
Post by 2011mnkdguy on Oct 31, 2016 17:25:50 GMT -5
Iam, Yes indeed!! For whatever it is worth out here in the Jayhawk State in the Flint Hills. Just yesterday I mailed information from Kansas to California to a relative. I enclosed an inhaler, a couple cartridges and the enclosed instructions from a new box. I tell everyone that I know that is in need. The huge thing I think is that they don't believe that a billion dollar drug had not presence on TV or elsewhere. Somebody let Mannkind know that mass advertising creates demand that create mass sales. Can anyone recall a $2 billion drug that did not put $30 to $50 million into a mass adv. campaign? I cannot. Yes Pfizer spent millions on Exubera. "Pfizer has not disclosed how much it's spending on the Exubera campaign, but it's likely in the tens of millions of dollars as well; the ads are already ubiquitous on TV, in magazines, and on Web sites such as dLife.com, which is associated with a CNBC television show for people with diabetes." |
|
|
|
Post by mango on Oct 31, 2016 22:12:49 GMT -5
Here is what mango is thinking.
If Trump becomes POTUS—Mr. William McCullough will schedule to have a meeting with the President. Mr. Trump will be offered to have his hair restoration redone for free by Samson Hair Restoration's finest surgeon. The hair redo ends up being so amazing that Mr. Trump will be changed forever. Meanwhile, the media catches on immediately and goes wild, and now everyone in the world has heard of this Samson Hair Restoration and Mr. William McCullough. Mr. McCullough dumps all his new dough into MannKind. During all his interviews and press conferences Mr. McCullough will be accompanied by a dreamboat inhaler in his front suit pocket and a big pin that says For MannKind. The media then becomes curious as to why Mr. McCullough would have a mispelled pin on his suit, and why he carries around a really small inhaler in his front suit pocket. The media soon discovers there is actually a company called MannKind and they make this inhaler. The media goes wild again and next thing you know every news network in the country is covering entire 1 hour segments on MannKind, sometimes the show goes past one hour. During this time Martin Shkreli is exposed and forever loses all credibility, and is forced to do Youtube videos for a living featuring him playing guitar and arguing with people.
Inhaled Epi ends up putting Mylan out of business the following year, and somehow TechnoVax and Mintaka foundation have enough money to go full production and everything they do is fastracked through the FDA.
RLS will still be a mystery, and will have replaced the trees with an imagine of a small hole in the ground with a seed.
|
|
|
|
Post by lakers on Nov 1, 2016 1:10:20 GMT -5
Pfizer scraps Exubera Pfizer withdraws its inhaleable insulin product Exubera from world markets despite spending significant amounts on manufacturing and marketing the product 30th September 2008 Pfizer has decided to withdraw its inhaleable insulin product Exubera from world markets despite spending significant amounts on manufacturing and marketing the product. Pfizer's CEO Jeffrey Kindler announced the withdrawal of Exubera on 18 October 2007, and the company incurred a USD 2.8bn charge for doing so. According to a report in the Wall Street Journal, while Kindler's decision to axe Exubera has made him popular among analysts for cutting back on costs, it has also caused ructions within the company's co-marketing partner, Nektar Therapeutics, and could undermine a key aspect of Pfizer's recovery strategy. Pfizer did not inform Nektar that it was going to remove Exubera from the market until the 18 October announcement. Nektar, understandably, has been pretty venomous in its criticism of Pfizer. The way in which Pfizer revealed the decision will no doubt make other existing and future partners nervous about doing business with the world's largest pharmaceutical company. A Pfizer spokesman defended the company's track record of partnering, saying that it had a strong record and was committed to building more. Despite the assurances, the lack of sensitivity on the part of Pfizer may come back to haunt it, when vying for other partners to help it plug its failing pipeline. So far in 2007, Pfizer has spent USD 775m to manufacture and promote Exubera, according to an estimate by Credit Suisse analysts. The reason is that insulin, due to its fragile small-molecule structure, costs more to manufacture than regular medicines.Normal business practice sees pharmaceutical companies keep their slow-selling or underperforming products on the market, in order to recoup as much revenue as possible. The present case is unusual, as the removal of any drug from the market is normally reserved for cases involving significant safety concerns, or in response to regulators' demands. Neither of these situations occurred with Exubera. For example, Pfizer's blockbuster cholesterol fighter Lipitor (atorvastatin) costs USD 0.08 for every USD 1 it sells. Exubera, on the other hand, costs Pfizer about USD 0.30 for every USD 1, according to the analysts. The company informed investors that Exubera racked up only USD 12m in sales, which was far from a break-even result. The reason Exubera costs so much to produce is that it is manufactured in Germany, shipped to California to be sprayed and turned into a powder, packaged into blisters elsewhere and then inserted into a device in another US state. Also, promoting the drug to primary-care doctors requires a big budget spend.
Pfizer also pays licensor Nektar approximately 15 per cent of sales. It also paid the company to manufacture the delivery device and spray-dry the powder. As a result, in Q1 FY07 Pfizer paid Nektar approximately USD 60m.Pfizer has spent in the region of USD 370m so far in 2007 to promote Exubera. Activities have included the sending of special diabetes educators to doctors to teach them how to use the new device, as well as DTC advertising investment. In comparison, say Credit Swiss analysts, the promotion of Pfizer's new cancer drug Sutent (imatinib), only cost Pfizer USD 200m. Nektar may take over sales and marketing Nektar is now free to market Exubera alone, according to WR Hambrecht & Co analysts. They say that Pfizer has manufactured enough of the product to last several years, given current demand. Because Nektar is a smaller company, its marketing costs would be much lower, so it would not have to sell as much Exubera to make a profit. Nektar could launch Exubera as a discounted product and lower the price 30 per cent or more to make it more attractive. Nektar is developing treatments for cystic fibrosis, cancer and a treatment for constipation as a side effect of pain drugs. In 2007, German-headquartered Bayer paid Nektar USD 50m to share the rights to an inhaled antibiotic it was working on, plus up to USD 125m more should Nektar meet development milestones. 30th September 2008 www.pmlive.com/pharma_news/pfizer_scraps_exubera_9168?SQ_DESIGN_NAME=2& |
|
